Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

2 trials in Phase 3/4

Results Transparency

0%

0 of 8 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
6(75.0%)
Phase 3
2(25.0%)
8Total
Phase 2(6)
Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT00133133Phase 2Completed

Efficacy and Safety of ALGRX 4975 in the Treatment of Postoperative Pain After Gall Bladder Removal

Role: lead

NCT00130949Phase 2Completed

ALGRX 4975 in the Treatment of Tennis Elbow

Role: lead

NCT00146198Phase 2Completed

Efficacy and Safety of ALGRX 4975 in Treatment of Postoperative Pain After Hernia Repair

Role: lead

NCT00132392Phase 2Completed

ALGRX 4975 After Total Knee Replacement

Role: lead

NCT00146185Phase 3Completed

Efficacy and Safety of ALGRX 3268 in Children Undergoing Minor Needle-Stick Procedures.

Role: lead

NCT00132405Phase 2Completed

Study of ALGRX 3268 for Needlestick Pain in Children

Role: lead

NCT00130962Phase 2Completed

ALGRX 4975 in the Treatment of Patients With Morton's Neuroma

Role: lead

NCT00140088Phase 3Completed

Efficacy and Safety of ALGRX 3268 in Management of Needlestick Pain in Children.

Role: lead

All 8 trials loaded